Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Roche's Tecentriq wins 12th FDA indication, for stage III colon cancer

9 October 2026 · By · Wire by Fusion42

Published

9 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 9 October 2026 · Fusion42 review

The US FDA approved Roche's Tecentriq in combination with chemotherapy for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, marking Tecentriq's 12th approved indication and the first immunotherapy regimen approved in this post-surgical setting.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 9 Oct 2026 and 11 Oct 2026.

◆ ◆ The Wire takeaway

You can expand drug development efforts into earlier-stage colorectal cancer with immunotherapy now FDA-approved post-surgery; competitors relying only on chemotherapy face a shrinking market.

◆ Coverage

3 sources · first reported 9 Oct 2026 · latest 11 Oct 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalimmunotherapyoncologycolon-cancerclinical-trials